3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precancerous Conditions
3
Breast Neoplasms
3
Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Adenomatous Polyposis Coli
2
Tobacco Use Disorder
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Intraductal Neoplasms
1
Pain
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Hypertension
1
Desmoid Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cytarabine
197
Azacitidine
143
Cyclophosphamide
136
fludarabine phosphate
112
fludarabine
97
Busulfan
96
venetoclax
95
Mycophenolic Acid
82
Whole-Body Irradiation
81
Tacrolimus
78
Peripheral Blood Stem Cell Transplantation
78
Decitabine
62
Filgrastim
56
Granulocyte Colony-Stimulating Factor
54
Cyclosporine
53
Melphalan
52
Methotrexate
51
Idarubicin
51
Daunorubicin
49
Antilymphocyte Serum
47
Clofarabine
43
Etoposide
41
Thiotepa
35
Gemtuzumab
34
Mitoxantrone
32
Stem Cell Transplantation
31
CPX-351
27
Specimen Handling
25
Radiotherapy
25
thymoglobulin
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, Myeloid, Acute
×
Sulindac
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn